Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fludrocortisone Acetate

FDA-approved product (tablet, oral), marketed as Florinef, Fludrocortisone Acetate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Fludrocortisone Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Adrenogenital syndrome
  • Chronic primary adrenal insufficiency
  • Primary adrenal insufficiency

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Mineralocorticoids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis29.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fludrocortisone Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fludrocortisone Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Mineralocorticoid Receptor in the Treatment of Severe Depression

    NCT00295347 · start 2005-12

    Registered record
    Registry ID
    NCT00295347
    Conditions
    Major Depression
    Interventions
    Spironolactone; fludrocortisone; escitalopram
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-12
    Completion
    2008-06
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depression
    InterventionSpironolactone; fludrocortisone; escitalopram
    PhaseNot applicable
    Registry statusCompleted

  • Orthostatic Hypotension in Rehabilitation Patients

    NCT00117585 · start 2005-11

    Registered record
    Registry ID
    NCT00117585
    Conditions
    Hypotension, Orthostatic
    Interventions
    Treatment Phase 1; Treatment Phase 2; Treatment Phase 3
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-11
    Completion
    2008-09
    Enrolment
    341

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypotension, Orthostatic
    InterventionTreatment Phase 1; Treatment Phase 2; Treatment Phase 3
    PhaseNot applicable
    Registry statusCompleted

  • Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy

    NCT00103597 · start 2005-01

    Registered record
    Registry ID
    NCT00103597
    Conditions
    Parkinson's Disease; Multiple System Atrophy; Orthostatic Hypotension
    Interventions
    Fludrocortisone; Domperidone; Conservative Measures for Orthostatic Hypotension
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-01
    Completion
    2005-09
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease; Multiple System Atrophy; Orthostatic Hypotension
    InterventionFludrocortisone; Domperidone; Conservative Measures for Orthostatic Hypotension
    PhasePhase 1
    Registry statusCompleted

  • Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

    NCT00001521 · start 1995-06-08

    Registered record
    Registry ID
    NCT00001521
    Conditions
    Congenital Adrenal Hyperplasia (CAH)
    Interventions
    Fludrocortisone; Hydrocortisone; Letrozole; Flutamide; Testolactone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1995-06-08
    Completion
    2024-04-01
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Adrenal Hyperplasia (CAH)
    InterventionFludrocortisone; Hydrocortisone; Letrozole; Flutamide +1 more
    PhasePhase 3
    Registry statusCompleted

  • Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock

    NCT02069288

    Registered record
    Registry ID
    NCT02069288
    Conditions
    Septic Shock
    Interventions
    Fludrocortisone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    2014-02
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionFludrocortisone; Placebo
    PhasePhase 3
    Registry statusWithdrawn